Rocket Pharmaceuticals Stock Analysis
RCKT Stock | USD 14.20 0.09 0.64% |
Rocket Pharmaceuticals is overvalued with Real Value of 13.23 and Target Price of 50.0. The main objective of Rocket Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Rocket Pharmaceuticals is worth, separate from its market price. There are two main types of Rocket Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Rocket Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Rocket Pharmaceuticals is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Rocket Stock trading window is adjusted to America/New York timezone.
Rocket |
Rocket Stock Analysis Notes
About 97.0% of the company shares are owned by institutional investors. The book value of Rocket Pharmaceuticals was at this time reported as 3.62. The company has Price/Earnings To Growth (PEG) ratio of 0.03. Rocket Pharmaceuticals recorded a loss per share of 2.73. The entity last dividend was issued on the 5th of January 2018. The firm had 1:4 split on the 5th of January 2018. Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey. Rocket Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 151 people. To find out more about Rocket Pharmaceuticals contact Gaurav MD at 609 659 8001 or learn more at https://www.rocketpharma.com.Rocket Pharmaceuticals Investment Alerts
Rocket Pharmaceuticals generated a negative expected return over the last 90 days | |
Rocket Pharmaceuticals has high historical volatility and very poor performance | |
Net Loss for the year was (245.59 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Rocket Pharmaceuticals currently holds about 321.37 M in cash with (194.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.87. | |
Over 97.0% of the company shares are owned by institutional investors | |
Latest headline from finance.yahoo.com: Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference |
Rocket Pharmaceuticals Upcoming and Recent Events
26th of February 2024 Upcoming Quarterly Report | View | |
2nd of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
26th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Rocket Largest EPS Surprises
Earnings surprises can significantly impact Rocket Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2018-08-08 | 2018-06-30 | -0.36 | -0.4 | -0.04 | 11 | ||
2020-08-05 | 2020-06-30 | -0.51 | -0.45 | 0.06 | 11 | ||
2020-11-04 | 2020-09-30 | -0.46 | -0.53 | -0.07 | 15 |
Rocket Pharmaceuticals Environmental, Social, and Governance (ESG) Scores
Rocket Pharmaceuticals' ESG score is a quantitative measure that evaluates Rocket Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Rocket Pharmaceuticals' operations that may have significant financial implications and affect Rocket Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.
Rocket Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Geode Capital Management, Llc | 2024-09-30 | 1.6 M | Boxer Capital Llc | 2024-09-30 | 1.5 M | Bank Of America Corp | 2024-06-30 | 1.2 M | Pictet Asset Manangement Sa | 2024-06-30 | 1.2 M | Cowen And Company, Llc | 2024-06-30 | 1.1 M | Novo A/s | 2024-09-30 | 1.1 M | Mpm Oncology Impact Management Lp | 2024-09-30 | 1.1 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 952 K | Perceptive Advisors Llc | 2024-09-30 | 931.9 K | Rtw Investments, Llc | 2024-06-30 | 17.7 M | Wellington Management Company Llp | 2024-06-30 | 9.2 M |
Rocket Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.29 B.Rocket Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.49) | (0.51) | |
Return On Capital Employed | (0.50) | (0.53) | |
Return On Assets | (0.43) | (0.46) | |
Return On Equity | (0.50) | (0.52) |
Management Efficiency
Rocket Pharmaceuticals has return on total asset (ROA) of (0.3448) % which means that it has lost $0.3448 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5927) %, meaning that it created substantial loss on money invested by shareholders. Rocket Pharmaceuticals' management efficiency ratios could be used to measure how well Rocket Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.51 in 2024. Return On Capital Employed is likely to drop to -0.53 in 2024. At this time, Rocket Pharmaceuticals' Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 29.4 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 292.8 M in 2024.Last Reported | Projected for Next Year | ||
Book Value Per Share | 5.86 | 6.16 | |
Tangible Book Value Per Share | 5.10 | 5.35 | |
Enterprise Value Over EBITDA | (10.51) | (11.04) | |
Price Book Value Ratio | 5.11 | 5.37 | |
Enterprise Value Multiple | (10.51) | (11.04) | |
Price Fair Value | 5.11 | 5.37 | |
Enterprise Value | 2.5 B | 2.6 B |
Understanding the management dynamics of Rocket Pharmaceuticals allows us to gauge its ability to sustain growth and profitability. This comprehensive analysis aids in determining the stock's value.
Beta 1.089 | Return On Assets (0.34) | Return On Equity (0.59) |
Technical Drivers
As of the 29th of November, Rocket Pharmaceuticals holds the Coefficient Of Variation of (1,032), risk adjusted performance of (0.07), and Variance of 15.01. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Rocket Pharmaceuticals, as well as the relationship between them.Rocket Pharmaceuticals Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Rocket Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Rocket Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Rocket Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Rocket Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Rocket Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Rocket Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Rocket Pharmaceuticals Outstanding Bonds
Rocket Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Rocket Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Rocket bonds can be classified according to their maturity, which is the date when Rocket Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
Boeing Co 2196 Corp BondUS097023DG73 | View | |
US77314EAA64 Corp BondUS77314EAA64 | View | |
HSBC Holdings PLC Corp BondUS404280DR76 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
US77310VAA26 Corp BondUS77310VAA26 | View | |
Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
US77313LAA17 Corp BondUS77313LAA17 | View |
Rocket Pharmaceuticals Predictive Daily Indicators
Rocket Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Rocket Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Rocket Pharmaceuticals Corporate Filings
F4 | 25th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 18th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 4th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 29th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 11th of September 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
F4 | 20th of August 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Rocket Pharmaceuticals Forecast Models
Rocket Pharmaceuticals' time-series forecasting models are one of many Rocket Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Rocket Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Rocket Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Rocket Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Rocket shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Rocket Pharmaceuticals. By using and applying Rocket Stock analysis, traders can create a robust methodology for identifying Rocket entry and exit points for their positions.
Last Reported | Projected for Next Year |
Current Rocket Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Rocket analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Rocket analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
50.0 | Strong Buy | 16 | Odds |
Most Rocket analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Rocket stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Rocket Pharmaceuticals, talking to its executives and customers, or listening to Rocket conference calls.
Rocket Stock Analysis Indicators
Rocket Pharmaceuticals stock analysis indicators help investors evaluate how Rocket Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Rocket Pharmaceuticals shares will generate the highest return on investment. By understating and applying Rocket Pharmaceuticals stock analysis, traders can identify Rocket Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow | 141.9 M | |
Common Stock Shares Outstanding | 84 M | |
Total Stockholder Equity | 492.6 M | |
Property Plant And Equipment Net | 87.6 M | |
Cash And Short Term Investments | 373.2 M | |
Cash | 55.9 M | |
Accounts Payable | 1772.00 | |
Net Debt | -30.9 M | |
50 Day M A | 16.7554 | |
Total Current Liabilities | 48.5 M | |
Other Operating Expenses | 259.7 M | |
Non Current Assets Total | 188.1 M | |
Non Currrent Assets Other | 1.9 M | |
Stock Based Compensation | 39.4 M |
Additional Tools for Rocket Stock Analysis
When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.